Lithocholate-3-O-glucuronide-induced cholestasis. A study with congenital hyperbilirubinemic rats and effects of ursodeoxycholate conjugates
- PMID: 8344113
- DOI: 10.1007/BF01308618
Lithocholate-3-O-glucuronide-induced cholestasis. A study with congenital hyperbilirubinemic rats and effects of ursodeoxycholate conjugates
Abstract
The mechanism of lithocholate-3-O-glucuronide-induced cholestasis is unknown. In this study, we investigated the cholestatic effects of this agent in a congenital hyperbilirubinemic rat, EHBR. We also studied the effects of ursodeoxycholate-3-O-glucuronide and tauroursodeoxycholate on lithocholate-3-O-glucuronide-induced cholestasis in rats. Lithocholate-3-O-glucuronide, administered at the rate of 0.1 mumol/min/100 g for 40 min, a cholestatic dose in control rats, failed to cause cholestasis in EHBR, and biliary lithocholate-3-O-glucuronide excretion was delayed. Biliary concentrations of this agent did not correlate with the severity of cholestasis. Both tauroursodeoxycholate and ursodeoxycholate-3-O-glucuronide, infused at the rate of 0.2 mumol/min/100 g for 120 min, completely inhibited cholestasis induced by lithocholate-3-O-glucuronide administered at the rate of 0.1 mumol/min/100 g for 40 min. Only tauroursodeoxycholate enhanced biliary lithocholate-3-O-glucuronide excretion. These findings indicate that lithocholate-3-O-glucuronide-induced cholestasis is induced by damage at the level of the bile canalicular membrane. Ursodeoxycholate-3-O-glucuronide inhibits this cholestasis, possibly by inhibiting the access of lithocholate-3-O-glucuronide to the bile canalicular membrane.
Similar articles
-
Enhanced biliary excretion of lithocholate-3-sulfate by ursodeoxycholate-3,7-disulfate infusion in Eisai hyperbilirubinemic rat (EHBR).Dig Dis Sci. 1998 Jan;43(1):188-92. doi: 10.1023/a:1018809028425. Dig Dis Sci. 1998. PMID: 9508524
-
Estradiol-17 beta-glucuronide-induced cholestasis. Effects of ursodeoxycholate-3-O-glucuronide and 3,7-disulfate.J Hepatol. 1993 Feb;17(2):241-6. doi: 10.1016/s0168-8278(05)80045-5. J Hepatol. 1993. PMID: 8445238
-
Colchicine inhibits lithocholate-3-O-glucuronide-induced cholestasis in rats.J Hepatol. 1995 Jan;22(1):88-93. doi: 10.1016/0168-8278(95)80265-7. J Hepatol. 1995. PMID: 7751593
-
[Intrahepatic cholestasis].Nihon Rinsho. 1996 Mar;54(3):788-93. Nihon Rinsho. 1996. PMID: 8904238 Review. Japanese.
-
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.Handb Exp Pharmacol. 2019;256:237-264. doi: 10.1007/164_2019_241. Handb Exp Pharmacol. 2019. PMID: 31236688 Review.
Cited by
-
Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.Clin Pharmacol Ther. 2013 Oct;94(4):533-43. doi: 10.1038/clpt.2013.122. Epub 2013 Jun 12. Clin Pharmacol Ther. 2013. PMID: 23756370 Free PMC article. Clinical Trial.
-
Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.Hepatol Commun. 2021 Dec;5(12):2035-2051. doi: 10.1002/hep4.1787. Epub 2021 Aug 27. Hepatol Commun. 2021. PMID: 34558841 Free PMC article.
-
Mechanisms of biliary excretion of lithocholate-3-sulfate in Eisai hyperbilirubinemic rats (EHBR).Dig Dis Sci. 1995 Aug;40(8):1792-7. doi: 10.1007/BF02212704. Dig Dis Sci. 1995. PMID: 7648982
-
Enhanced biliary excretion of lithocholate-3-sulfate by ursodeoxycholate-3,7-disulfate infusion in Eisai hyperbilirubinemic rat (EHBR).Dig Dis Sci. 1998 Jan;43(1):188-92. doi: 10.1023/a:1018809028425. Dig Dis Sci. 1998. PMID: 9508524
-
PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.Cells. 2024 Aug 1;13(15):1296. doi: 10.3390/cells13151296. Cells. 2024. PMID: 39120326 Free PMC article. Review.